'Pharma News'
| Alembic Inks Licensing Pact with Accu-Break Pharma |
New Delhi, Aug 8, 2012
Alembic Pharmaceuticals Ltd said it has entered into a drug development and licensing agreement with the US-based Accu-Break Pharmaceuticals under which it plans to launch over five generic drugs in the next two to three years.
Under the agreement, new brand of products will be developed using the technology of Accu-Break Pharmaceuticals (ABP) that makes it easier to split tablets by hand into accurate dosages, the firm said.
“Using this technology which makes it easier and safer for patients and caregivers to adjust dosage of tablets, we plan to launch five to six generic products in various therapeutic areas,” a senior company official said.
When asked by when the products would hit the market, the official said: “We are looking at a time frame of two to three years.”
The first product using Accu-Break technology that Alembic will seek USFDA marketing approval for is the popular anticoagulant medication warfarin, the official said.
|
|
| |
|
|
|
